Get the Stockscreener App
3.39
3.14%
-0.11
After Hours:
3.56
0.17
+5.01%
Vistagen Therapeutics Inc stock is traded at $3.39, with a volume of 318.88K.
It is down -3.14% in the last 24 hours and up +18.53% over the past month.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
See More
Previous Close:
$3.50
Open:
$3.53
24h Volume:
318.88K
Relative Volume:
0.75
Market Cap:
$104.01M
Revenue:
$875.70K
Net Income/Loss:
$-39.57M
P/E Ratio:
-2.5255
EPS:
-1.3423
Net Cash Flow:
$-33.65M
1W Performance:
-4.51%
1M Performance:
+18.53%
6M Performance:
+21.51%
1Y Performance:
+6.27%
1-Day Range:
$3.37
$3.53
1-Week Range:
$3.37
$3.64
52-Week Range:
$1.90
$3.88
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
Name
Vistagen Therapeutics Inc
Sector
Industry
Phone
650-577-3600
Address
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare VTGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTGN
Vistagen Therapeutics Inc
|
3.39 | 109.53M | 875.70K | -39.57M | -33.65M | -1.3423 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-07-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-07-23 | Upgrade | Maxim Group | Hold → Buy |
| Jul-22-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-22-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-22-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| May-20-21 | Initiated | Robert W. Baird | Outperform |
| Feb-18-21 | Initiated | Jefferies | Buy |
| Jan-04-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-27-18 | Initiated | Maxim Group | Buy |
| Feb-08-18 | Reiterated | Chardan Capital Markets | Buy |
| Mar-28-17 | Initiated | Maxim Group | Buy |
View All
Vistagen Therapeutics Inc Stock (VTGN) Latest News
How to manage a losing position in Vistagen Therapeutics Inc.Weekly Gains Report & Smart Money Movement Tracker - Newser
Price action breakdown for Vistagen Therapeutics Inc.Weekly Loss Report & High Conviction Trade Alerts - Newser
What Fibonacci levels say about Vistagen Therapeutics Inc. reboundWeekly Risk Report & AI Forecast Swing Trade Picks - Newser
Risk vs reward if holding onto Vistagen Therapeutics Inc.Share Buyback & Technical Entry and Exit Tips - Newser
Regression analysis insights on Vistagen Therapeutics Inc. performancePortfolio Performance Summary & Free Long-Term Investment Growth Plans - Newser
Forecasting Vistagen Therapeutics Inc. price range with options dataJuly 2025 Drop Watch & Daily Stock Trend Reports - Newser
Vistagen Therapeutics Inc. stock retracement – recovery analysisJuly 2025 Recap & Weekly Market Pulse Alerts - Newser
Tick level data insight on Vistagen Therapeutics Inc. volatilityJuly 2025 Highlights & Technical Entry and Exit Alerts - Newser
Price momentum metrics for Vistagen Therapeutics Inc. explained2025 Valuation Update & Risk Controlled Stock Pick Alerts - Newser
Vistagen Therapeutics Inc. stock outlook for YEARWeekly Trade Review & High Win Rate Trade Alerts - Newser
Is Vistagen Therapeutics Inc. stock bottoming out2025 Volatility Report & Growth-Oriented Investment Plans - Newser
Is Vistagen Therapeutics Inc. still worth holding after the dipExit Point & Risk Adjusted Swing Trade Ideas - Newser
Using data tools to time your Vistagen Therapeutics Inc. exit2025 Big Picture & Daily Stock Trend Watchlist - Newser
Why Vistagen Therapeutics Inc. stock attracts strong analyst attentionMarket Volume Report & Capital Efficient Trading Techniques - Newser
Analyzing recovery setups for Vistagen Therapeutics Inc. investors2025 Volume Leaders & Daily Risk Controlled Trade Plans - Newser
Statistical indicators supporting Vistagen Therapeutics Inc.’s strengthVolume Spike & Weekly Breakout Watchlists - Newser
How to interpret RSI for Vistagen Therapeutics Inc. stockPrice Action & Risk Managed Investment Signals - Newser
Can Vistagen Therapeutics Inc. rally from current levelsJuly 2025 Market Mood & Safe Entry Momentum Tips - Newser
Institutional scanner results for Vistagen Therapeutics Inc.2025 Price Momentum & Fast Exit Strategy with Risk Control - Newser
How to build a custom watchlist for Vistagen Therapeutics Inc.July 2025 Outlook & Short-Term Trading Alerts - Newser
Measuring Vistagen Therapeutics Inc.’s beta against major indicesJuly 2025 Trade Ideas & Free Real-Time Market Sentiment Alerts - Newser
Published on: 2025-09-10 11:04:49 - Newser
Can trapped investors hope for a rebound in Vistagen Therapeutics Inc.Weekly Profit Recap & Verified Trade Idea Suggestions - Newser
Vistagen Therapeutics Inc.’s volatility index tracking explainedPortfolio Return Report & Low Drawdown Trading Strategies - Newser
How to monitor Vistagen Therapeutics Inc. with trend dashboardsTrade Exit Summary & Low Risk High Win Rate Picks - Newser
Can Vistagen Therapeutics Inc. Bounce Back From Weekly LowWeekly Risk Summary & Long-Term Capital Growth Ideas - Newser
Ketamine treatment Market Set to Witness Significant Growth - openPR.com
Late-Stage Biotech Vistagen Showcasing Novel Nasal Neuroscience Platform at TD Cowen Summit - Stock Titan
Is this a good reentry point in Vistagen Therapeutics Inc.Forecast Cut & Safe Capital Allocation Plans - Newser
Vistagen Therapeutics Inc Stock (VTGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):